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Abstract
Interleukin(IL)-18 is a pleiotrophic cytokine with functions in immune modulation, angiogenesis and bone metabolism. In
this study, the potential of IL-18 as an immunotherapy for prostate cancer (PCa) was examined using the murine model of
prostate carcinoma, RM1 and a bone metastatic variant RM1(BM)/B4H7-luc. RM1 and RM1(BM)/B4H7-luc cells were stably
transfected to express bioactive IL-18. These cells were implanted into syngeneic immunocompetent mice, with or without
an IL-18-neutralising antibody (aIL-18, SK113AE4). IL-18 significantly inhibited the growth of both subcutaneous and
orthotopic RM1 tumors and the IL-18 neutralizing antibody abrogated the tumor growth-inhibition. In vivo neutralization of
interferon-gamma (IFN-c) completely eliminated the anti-tumor effects of IL-18 confirming an essential role of IFN-c as a
down-stream mediator of the anti-tumor activity of IL-18. Tumors from mice in which IL-18 and/or IFN-c was neutralized
contained significantly fewer CD4+ and CD8+ T cells than those with functional IL-18. The essential role of adaptive
immunity was demonstrated as tumors grew more rapidly in RAG12/2 mice or in mice depleted of CD4+ and/or CD8+ cells
than in normal mice. The tumors in RAG12/2 mice were also significantly smaller when IL-18 was present, indicating that
innate immune mechanisms are involved. IL-18 also induced an increase in tumor infiltration of macrophages and
neutrophils but not NK cells. In other experiments, direct injection of recombinant IL-18 into established tumors also
inhibited tumor growth, which was associated with an increase in intratumoral macrophages, but not T cells. These results
suggest that local IL-18 in the tumor environment can significantly potentiate anti-tumor immunity in the prostate and
clearly demonstrate that this effect is mediated by innate and adaptive immune mechanisms.
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Introduction
Prostate cancer (PCa) is the second most common cancer of
men in the world [1]. Globally in 2002, an estimated 679,000 men
were newly diagnosed with PCa and an estimated 221,000 died
from it [1]. PCa that metastasizes to bone is virtually incurable [2].
PCa is often considered as an ideal candidate for cancer
immunotherapy because of the expression of prostate specific
molecules and the non-essential nature of the prostate gland [3].
Experiments using mice have shown that the immune stimulatory
effects of some cytokines can induce strong anti-tumor immunity
[4]. This involves both innate and adaptive immune mechanisms
that function complimentarily to promote tumor immunity [5].
Interleukin (IL)-18 is an 18kd protein that has potential as an
anti-cancer agent. It belongs to the IL-1 family of cytokines and
is produced by many cell types including Kupffer cells [6],
macrophages [7], dendritic cells [8], keratinocytes [9], intestinal
epithelial cells [10], osteoblasts [11], astrocytes and microglial cells
[12]. The IL-18 receptor (IL-18R) is expressed on macrophages,
neutrophils, natural killer (NK) cells and endothelial cells and can be
up-regulated on Th1 and B cells by IL-12 [13]. Like IL-1b, pro-IL-
18 lacks a signal peptide and is activated into its mature form
following cleavage by IL-1b converting enzyme (ICE) [14,15]. IL-
18, originally described as ‘interferon-gamma (IFN-c) inducing
factor’ (IGIF), is a potent inducer of IFN-c by T cells and natural
killer (NK) cells and is synergistic in this function with IL-12 [16].
IL-18 is known to drive the differentiation of CD4+ T cells to the
Th1 phenotype, favouring cell-mediated immune responses,
although it can also promote Th2 responses under some conditions
[16]. IL-18 induces the proliferation and enhances the cytotoxicity
of both T and NK cells [13]. It activates macrophages to produce
IFN-c and is chemotactic for neutrophils [17,18]. IFN-c, a
pleiotrophic Th1-promoting cytokine downstream of IL-18, induces
expression of MHC class I molecules and Fas (promoting cytotoxic
CD8+ T cell responses) and up-regulates MHC class II molecules
(promoting antigen-specific CD4+ T cell responses) [19].
IL-18 has anti-tumor effects in several murine models of cancer.
IL-18 gene-transfer into tumor cells, alone [20,21,22] or in
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combination with IL-12 [23,24,25] or IL-23 [26], results in tumor
growth inhibition. IL-18-mediated tumor stasis is also achieved by
administrating the cytokine via intraperitoneal [27,28,29,30],
intravenous [27], intratumoral [31] and peritumoral [32] routes.
IL-18 as an adjuvant enhances the anti-tumor efficacy of dendritic
cell-based vaccines [33,34,35] and suicide gene therapies [36]. In
those studies, the anti-tumor effects of IL-18 were mediated through
enhancement of anti-tumor immunity or inhibition of tumor
angiogenesis. Here we investigated the potential of IL-18 as a
cancer agent for PCa by using a murine orthotopic model of
prostate carcinoma, the RM1 cell line. We provide proof-of-concept
that RM1 tumors engineered to secrete bioactive IL-18 exhibit
significant growth inhibition of prostate tumors that is mediated by
immune potentiation. Whilst in early experiments RM1 tumors
were grown subcutaneously, we subsequently generated tumors
orthotopically (in the prostate) to better model human disease.
Furthermore, direct injection of IL-18 into tumors, a clinically
relevant means of administration, also inhibited tumour growth.
Furthermore, direct injection of IL-18 into tumors, a clinically
relevant means of administration, also inhibited tumor growth.
Materials and Methods
Cell lines
RM1 cells were obtained from Dr. Tim Thompson (Baylor
College of Medicine, TX, USA) [37]. RM1-IL18, RM1-LACZ
and RM1(BM) and derivatives thereof were developed in-house
from the RM1 parental cell line. The hybridoma cell line A2,
which produces an IgG1 antibody (Ab) against MOPC cancer cells
used as a negative control antibody, was provided by Dr Andrew
Collins (University of New South Wales, Australia). All these cell
lines were maintained in Dulbecco’s modified Eagle medium
(DMEM) containing 10% Fetal Calf Serum (FCS) and 2 mM
L-glutamine (complete DMEM). The hybridomas SK113AE4
(aIL-18) [38] obtained from Prof. Irmgard Fo¨rster (Institut
fu¨r Umweltmedizinische Forschung, Germany) and XMG1.2
(aIFN-c) were cultured in complete RPMI media (RPMI with
10% Fetal Calf Serum, 2 mM L-glutamine). Cells were incubated
at 37uC in a humidified atmosphere of 5% C02/air.
Ethics Statement
All studies were in accordance with guidelines of the Animal
Care and Ethics Committee (ACEC) of the University of New
South Wales (ACEC IDs: 06/45A, 06/81B, 08/101B).
Mice
Male C57BL/6 and C57BL/6 RAG12/2, 4–6 weeks old,
were purchased from Laboratory Animal Services, University of
Adelaide and Animal Resources Centre, Western Australia,
respectively. All mice were maintained at the Biological Resources
Centre (BRC), University of New South Wales, Sydney, Australia.
Generation of RM1-IL18 and RM1(BM)/IL-18lo-luc cell lines
The RM1-LACZ cells are plasmid transfected to express the E.
coli LacZ gene. The RM1(BM) cell line is a bone-metastatic
derivative of RM1 [39] and RM1(BM)/IL18lo-luc expresses
constitutively active murine IL-18 and firefly luciferase. RM1-
IL18: RM1 cells were transfected with pVITRO2-GFP/mIL-18
using lipofectamine reagent (Invitrogen, CA, USA) according
to the manufacturer’s instructions. Briefly, the 3136 bp DNA
fragment (which contains the GFP gene) of pVITRO2/GFP/
LacZ (In vivogen, CA, USA) was excised with the Nhe I and AvrII
restriction enzymes and inserted into pVITRO2-mcs (In vivogen,
CA, USA), replacing the 2452 bp DNA fragment between
multiple cloning sites 1 and 2 (now termed ‘pVITRO2-mcs/
GFP’). The hybrid mIL-18 gene, containing the signal sequence
of IFN-b, excised from the pCEXV3/hybrid mIL-18 plasmid
(provided by Dr Isao Hara, Kobe University School of Medicine,
Japan) was inserted into the pVITRO2-mcs/GFP plasmid (now
termed ‘pVITRO2-GFP/mIL-18’) via the EcoRI restriction sites.
For transfection, RM1 cells cultured to 80% confluence in 10 cm2
wells were incubated with a complex (composed of 1 mg of DNA
construct and 10 ml of Lipofetamine 2000) diluted in 2.5 ml of
serum free Opti-Mem (Invitrogen, CA, USA). Selection for
transfectants began 72 hours post transfection by culture in
complete DMEM containing hygromycin b (Invitrogen, CA,
USA) at 400 mg/ml and maintained at 200 mg/ml once stable
populations were generated (RM1-IL18 cells). A control cell line
(RM1-LACZ) in which the plasmid contained the gene for LACZ
in place of mIL-18, was generated in a similar way. RM1(BM)/IL-
18lo-luc: The RM1(BM) cell line was transfected with plasmid
phCMV-CLUC containing the gene for firefly luciferase under
control of the human CMV promoter (Genlantis, CA, USA) and a
luciferase expressing clone was isolated which was named
RM1(BM)/B4H7-luc (Power et al., unpublished). RM1(BM)/
B4H7-luc cells were subsequently transfected with pVITRO2-
blasti/mIL-18. Briefly, the 605 bp DNA fragment containing the
hybrid IL-18 gene was excised from pCEXV3/hybrid mIL-18
plasmid and inserted into pVITRO2-blasti/mcs (In vivogen, CA,
USA) at the BglII and XhoI restriction sites. The protocol for
transfection was similar to that of RM1-IL18 except that selection
involved blasticidin at 10 mg/ml (In vivogen, CA, USA).
Determination of IL-18 expression by RM1-IL18 and
RM1(BM)/IL18lo-luc
Conditioned media were prepared by culturing tumor cells to
80% confluence (in T75 flasks) followed by 48 hour incubation in
10 ml of serum-free DMEM. IL-18 was detected by sandwich
ELISA assay using the Pharmingen OPTEIA mouse anti-IL-18
antibody set (BD Biosciences, CA, USA). The concentration of IL-
18 in conditioned media of RM1-IL18 cells was interpolated from
results obtained for purified recombinant IL-18 (Medical &
Biological Laboratories, Japan) at concentrations ranging from
0 ng/ml to 100 ng/ml; limit of detection of the ELISA: 12 ng/ml.
Purification of monoclonal antibodies for in vivo studies
The hybridomas A2 (mouse IgG1), SK113AE4 cells (aIL-18;
mouse IgG1) and XMG1.2 (aIFN-c; rat IgG1) were cultured as
described until the media were exhausted, and the secreted
antibody was harvested. The hydridoma culture supernates were
passed through a protein G sepharose column (Amersham
Biosciences, NJ, USA). The bound IgG was eluted using 0.1 M
glycine, pH 3, and the pH was immediately neutralized with 1 M
Tris-base, pH 8.0. The eluates were dialysed against PBS and the
purity of antibody preparations was determined by SDS-PAGE
followed by Coomassie blue (Biorad, CA, USA) staining. The
concentration was determined by BCA protein assay (Pierce
Biotechnology, IL, USA).
Tumorigenesis studies
Cultured RM1-IL18, RM1-LACZ, RM1(BM)/B4H7-luc and
RM1(BM)/IL-18lo-luc cells were lifted from culture flasks with
trypsin in PBS, washed twice with PBS and resuspended in PBS.
Cell counts were performed with a hemocytometer and viability
was assessed by trypan blue exclusion. All animal experiments
involved implantation with either 66105 or 26106 tumor cells in
mice (see figure legends for individual experiments). Subcutaneous
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implantation of cells was performed on the right shoulder or flank
of mice in 100 mL volume. These tumors were measured using
electronic calipers every 2-3 days and tumor volume calculated
from the formula for the volume of an elipse: V = p/6(d1.d2)
3/2,
where d1 and d2 are two perpendicular tumor dimensions [40].
For intraprostatic implantation, the hair was removed from the
abdomen of mice using a depilatory and the mice were
anesthetised with isoflurane inhalation anesthetic. A low abdom-
inal transverse incision was made through the skin and abdominal
muscle and the bladder was grasped with forceps and pulled
through the incision, exposing the prostate. Tumor cells were
injected into the ventral prostate in 50 ml volume. The bladder was
returned to the abdomen and the incision closed with sutures. In
vivo cytokine neutralization was accomplished by administering
500 mg of neutralizing aIL-18 antibody and/or aIFN-c antibody,
or A2 control antibody into the tail vein or intraperitoneally 30
minutes prior to tumor-cell implantation. Each experimental
group consisted of 5–10 mice. All mice were weighed and checked
for signs of distress regularly. Abdominal palpation was used to
monitor tumor size. For intratumoral injection of IL-18,
RM1(BM)/B4H7-luc cells were implanted on the right flank of
mice. 5 daily injections of 1.5 mg of IL-18 in 15 ml volume
commenced when the tumors reached 6 mm 6 6 mm in
dimension. Control mice were injected with vehicle only.
Depletion of immune cell subsets in tumor studies
For depletion of CD4+ and CD8+ T cells, mice were injected
intraperitoneally with 100 mg of MAbs GK1.5 or 2.43 (both from
Bio X Cell, NH, USA), respectively, four days and two days
prior to tumor-cell implantation and subsequently every 4 days
thereafter until day 18. For depletion of NK cells, mice were
treated with 20 ml of anti-asialo GM1 anti-serum (Wako Pure
Chemicals, TX, USA) four days and one day prior to tumor-cell
implantation, and every 5 days thereafter. Depletion of .95% of
each immune cell subset was confirmed by flow cytometry
performed on peripheral blood on day 7, and again on spleen
cells following necropsy on day 17.
Tumor bioluminescence imaging
Bioluminescent imaging was performed using a Xenogen IVIS
Lumina (Xenogen, CA, USA). For in vitro imaging, bioluminescent
RM1(BM)/IL-18lo-luc cells were seeded at 50,000 cells/well down
to 50 cells/well (2-fold serial dilution) in 96-well plates. D-luciferin
(Xenogen, CA, USA) was added to each well (final concentration
was 150 mg/ml of media) 3–5 mins prior to imaging. For in vivo
imaging, mice were injected ip with D-luciferin diluted in PBS
(15 mg/ml stock) at 150 mg/kg. Mice were anaesthetised and
imaged 8–12 minutes after injection with D-luciferin. Biolumines-
cence was analysed using Living Imagine software (Xenogen, CA,
USA). For in vivo imaging, the total flux in photons/second (p/s)
within each defined region of interest provides a surrogate of
tumor size.
Flow cytometric analysis
The cellular profile of tumor draining lymph nodes was
analysed by flow cytometry using the FACScan (Becton Dickinson,
CA, USA). Para-aortic lymph nodes were disintegrated by
compression between the frosted sides of 2 microscope slides,
and suspended in PBS containing 5% turbo calf serum. Removal
of tissue clumps and debris was achieved by layering the
suspension over 2 ml of cold FCS, followed by collection of the
cells which remain suspended above the serum. T cells were
stained with aCD3-FITC antibody (17A2), aCD4-PE (H129.19)
and biotinylated-aCD8a antibody (53-6.7) plus PerCP-streptavidin
(BD Biosciences Pharmingen, CA, USA). NK cells were detected
using aNK1.1-PE (PK136) and aCD3-FITC antibodies. B cells
were identified by incubation with aI-Ab (MHC-II)-FITC
antibody (AF6-120.1) and biotinylated-aCD19 (1D3) plus
PerCP-streptavidin. All antibodies were from BD Biosciences
Pharmingen, CA, USA. These antibodies do not cross react with
the cell-depleting antibodies.
Measurement of cytokines in mice serum
The concentration of IFN-c, IL-12, GM-CSF, MCP-1,
RANTES and IL-4 in serum collected at necropsy was determined
using BD Cytometric Bead Array technology (BD Biosciences,
CA, USA), according to the manufacturer’s instructions. Briefly,
the microbeads, which have distinct fluorescence intensities and
are coated with capture antibodies for each cytokine, were
incubated with recombinant standard or serum (diluted 1:6) for
1 hour. PE-conjugated detection antibodies were then added and
incubated for a further 1 hour. The beads were washed and
resuspended in wash buffer and then analysed using a BD
FACS Canto (BD Biosciences Pharmingen, CA, USA). Concen-
tration of cytokine level was determined using CBA analysis
software.
Histochemical and immunohistochemical staining
For histological examination, resected tumors were fixed in
zinc-fixative (BD Biosciences Pharmingen, CA, USA) and
embedded in paraffin for sectioning. Sections of 5 mm thickness
were processed using standard protocols. Haematoxylin & Eosin
(H&E) staining was carried out to assess tissue morphology and for
assessment of cellular infiltration. Immunohistochemical staining
was performed using primary antibodies to CD8a (53-6.7), CD4
(H129.19) (all from BD Biosciences Pharmingen, CA, USA),
asialo-GM1 (Wako Pure Chemicals, TX, USA), F4/80 (BM8)
(eBioscience, San Diego, CA, USA), caspase-3 (Cell Signaling
Technology, MA, USA), Ki-67 (TEC-3) (DAKO, Glostrup,
Denmark) and IL-18 (Santa Cruz, CA, USA). The secondary
antibodies used were biotinylated rabbit a-rat, biotinylated goat a-
rabbit or biotinylated rabbit a-goat (all from Vector Laboratories,
CA, USA). Histochemical detection was achieved using Biotin-
Avidin Complex (Vector, CA, USA) followed by incubation
with 3,39 Diaminobenzidine (DAB) substrate (DAKO, Glostrup,
Denmark).
Assessment of tumor-infiltrating immune cells
Histological assessment was performed using an Olympus BX51
microscope. Tumor sections stained for CD8 and CD4 were
examined by microscopy at 2006magnification for assessment of
numbers of tumor-infiltrating lymphocytes. Entire sections were
progressively scanned and the number of lymphocytes in each field
of view was recorded in a semi-quantitative fashion as either zero,
between one and ten, between eleven and fifty or greater than fifty.
This approach not only provides an indication of the number of
lymphocytes infiltrating the tumor, but also their relative
distribution within the tumor. Tumors stained for F4/80, Asialo
GM1, Caspase-3, Ki67 and H&E were also scanned at 2006
magnification and were qualitatively assessed as described in
Results.
Statistical Analysis
All statistical tests were performed using GraphPad Prism
software. Appropriate statistical tests were employed depending on
the nature of the data being analysed. Refer to the figure legends
for specific tests used for data from individual experiments.
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Results
Confirmation of IL-18 expression by RM1-IL18 cells
IL-18 was detected in the conditioned media of RM1-IL18 cells
and RM1(BM)/IL18lo-luc cells by ELISA (106 cells released
.200 ng and ,20 ng respectively in 48 hours). IL-18 expression
was also confirmed by western blot (data not shown) prior to each
experiment. IL-18 was not expressed by RM1 parental, RM1-LACZ
or RM1(BM)/B4H7-luc cells. The biological activity of the secreted
IL-18 was confirmed by its ability to induce IFN-c production from
murine splenic T cells (Figure S1 A). IFN-c production was induced
in a dose dependent manner following incubation with varying
concentrations of RM1-IL18 conditioned media. Immunohisto-
chemically, RM1-IL18 tumors grown in the prostate were positive
for IL-18, confirming its secretion in vivo (Figure S1 B).
IL-18 inhibits the growth of subcutaneous and
orthotopic prostate carcinomas
To investigate the effects of local secretion of IL-18 by tumors
on tumor growth in vivo, RM1-IL18 cells were implanted
subcutaneously or intraprostatically into syngeneic C57BL/6 mice
with or without the IL-18-neutralizing antibody (aIL-18),
SK113AE4. 100% of mice that were injected with RM1-IL18
cells subcutaneously and received the aIL-18 Ab treatment
developed tumors (10 of 10); in contrast only 33% of mice that
did not receive the neutralizing antibody (Ctrl group) developed
tumors (4 of 12) (Fig. 1 A). The subcutaneous tumors that
developed in the latter group showed delayed onset and were
significantly smaller (p = 0.0002) at necropsy compared to those
given aIL-18 (Fig. 1 B), indicating that IL-18 not only prevented
tumor formation but also suppressed the growth of those that
developed. In mice implanted subcutaneously with the control cell
line, RM1-LACZ, IL-18 neutralization resulted in significantly
larger tumors (p = 0.0477) (Fig. 1 C), suggesting that endogenous
IL-18 plays a role in tumor immunity. All mice implanted with
RM1-IL18 tumor cells orthotopically (in the prostate) developed
tumors (Fig. 1 D), however, neutralization of IL-18 through aIL-
18 treatment resulted in significantly larger tumors (p,0.001).
Anti-tumor effects of IL-18 require IFN-c
Since IFN-c is an effector molecule downstream of IL-18 with
important functions in Th1-responses, we hypothesized it may
mediate the anti-tumor effects of IL-18. To investigate this, RM1-
IL18 cells were implanted orthotopically in C57BL/6 mice and
treated with neutralizing antibodies to IL-18, IFN-c or both.
Neutralization of IL-18 and/or IFN-c resulted in significantly larger
tumors compared to those given the control antibody (Ctrl) (Fig. 2 A).
As previously, tumors in mice treated with the IL-18-neutralizing
antibody alone were larger than controls (Ctrl group). Neutralization
of IFN-c alone resulted in larger tumors than those in Ctrl mice or
aIL-18 treated mice (Fig. 2 A). Co-neutralization of IL-18 and IFN-c
did not result in tumors larger than those given IFN-c antibody alone.
Figure 1. IL-18 inhibits RM1 tumor growth. IL-18 expression by RM1 murine prostate carcinoma cells inhibits the in vivo growth of these cells
implanted subcutaneously and orthotopically into syngeneic mice, but not when IL-18 is inactivated by the IL-18-neutralizing antibody (aIL-18),
SK113AE4. A) Post mortem weights of RM1-IL18 tumors from mice treated with (aIL-18) or without (Ctrl) the IL-18-neutralizing antibody after
subcutaneous implantation of 66105 tumor cells. Results in (A) are from two independent experiments (circles and triangles) in which mice were
killed on day 14. B) Growth rates of subcutaneous RM1-IL18 tumors in mice with or without IL-18-neutralization are shown. C) Post mortem weights
of control RM1-LACZ tumors (which do not express IL-18) from mice treated with aIL-18 or without (Ctrl), 11 days following subcutaneous injection of
66105 cells. Post mortem weights of RM1-IL18 tumors 12 days after 66105 cells were implanted orthotopically, with or without IL-18 neutralization
are shown in (D). Statistical analysis performed for (A) was the Mann-Whitney test, and (c) and (d) was the unpaired T-test. Significant p values are
shown where appropriate.
doi:10.1371/journal.pone.0024241.g001
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IL-18 correlated with significant tumor infiltration of
neutrophils, macrophages, CD8+ T cells and CD4+ T cells
but not NK cells
In RM1-IL18 tumors (from Fig. 2 A), IL-18 correlated with
significantly greater tumor infiltration of CD8+ (Fig. 2 B) and
CD4+ cells (Fig. 2 C). In the Ctrl group, 18.8% percent of the
tumor contained .50 CD8+ cells per microscopic field compared
to 6.6%, 2.9% and 0.0% respectively for groups that received
neutralizing antibodies to IL-18, IFN-c, or both (Fig. 2 B, Fig. 3
A & B). Furthermore, 13.9% of the tumor in the Ctrl group
contained between 11 and 50 CD4+ cells per microscopic field
compared to 4.3%, 6.2% and 1.8% respectively for the mice in
which IL-18, IFN-c, or both were neutralized (Fig. 2 C and Fig. 3
C & D). Profound tumor-infiltration of macrophages was observed
in the Ctrl treatment group, but less so when IL-18 was inactivated
(Fig. 3 E & F). H&E staining revealed that mice in which the IL-18
was not neutralized had greater numbers of neutrophils within
tumors, compared to those from mice given aIL-18 (Fig. 3 G & H).
No correlation between IL-18 and numbers of NK cells was found
in normal C57BL/6 mice (Fig. 3 I & J).
We also examined the degree of apoptosis and cell proliferation
in RM1-IL18 tumors in normal mice from Fig. 2. Tumors from
mice given the Ctrl antibody had more staining for the apoptotic
marker, caspase-3, compared to those from mice given aIL-18,
aIFN-c, or both (Figure S2 A & B, E). An inverse correlation was
observed with Ki-67 staining (Figure S2 C & D, E).
Innate and adaptive immune mechanisms mediate the
anti-tumor effects of IL-18
RM1-IL18 tumors grown in the prostate of RAG12/2 mice,
which lack T and B cells, were significantly larger than those from
their corresponding treatment group in normalC57BL/6mice (Fig. 4
A). This demonstrates an important role for adaptive immunity in
mediating the anti-tumor effects of IL-18. In both mouse strains,
aIL-18 treatment resulted in significantly larger tumors than in
corresponding Ctrl mice, indicating that apart from adaptive
immunity, other mechanisms including innate immune mechanisms
are involved in this tumor inhibitory effect. Flow cytometric analysis
from lymph nodes of normal tumor-bearing C57BL/6 mice showed
that aIL-18 treatment was associated with greater cellularity in the
tumor-draining lymph node (Fig. 4 B). However, as a percentage of
total cells, CD8+ T cells, CD4+ T cells (Fig. 4 C) and NK cells (Fig. 4
D) were higher when IL-18 was present.
RM1-IL18 tumors generated in immunocompromised RAG12/2
mice (from Fig. 4 A) from the Ctrl treatment group had greater
infiltration of macrophages and neutrophils compared to IL-18-
neutralized tumors (Figure S3 A–D) showing tumor infiltration of
macrophages and neutrophils in RAG12/2 mice). However, the
abundance of macrophages in tumors of RAG12/2 mice was less
marked than in normal C57BL/6 mice. Noteworthy is that
neutrophils appeared to localize within the apoptotic/necrotic
regions of the tumor whereas the macrophages infiltrated the viable
areas. Similar to normal mice, no correlation between IL-18 and
numbers of NK cells was found in RAG12/2mice (Figure S3 E & F).
CD4+ and CD8+ T cells, and NK cells are involved in the
anti-tumor effect of IL-18
Bioluminescent RM1(BM)/IL-18lo-luc tumors (Figure S1 C),
which confirms that RM1(BM)/IL-18lo-luc cells are bioluminescent
in vitro prior to implant) generated orthotopically were significantly
larger in mice depleted of CD4+ and/or CD8+ T cells, compared to
undepleted mice (Ctrl) (Fig. 5 A). Depletion of NK cells also resulted
in larger tumors compared to the Ctrl group, although this effect not
statistically significant (Fig. 5 A). Neutralisation of IL-18 resulted in
larger tumors compared to Ctrl treatment, confirming previous
observations (Fig. 5 A). Tumors from mice depleted of immune cell
subsets had faster growth rates throughout the experiment as
assessed by bioluminescent imaging (Fig. 5B–D ).
Intratumoral injection of IL-18 into pre-formed
subcutaneous tumors inhibits their growth
Direct injection of 1.5 mg of recombinant IL-18 into pre-
established subcutaneous RM1(BM)/B4H7-luc tumors for 5
consecutive days inhibited their growth (Fig. 6 A). Vehicle injection
Figure 2. The anti-tumor effects of IL-18 are mediated
predominantly through IFN-c. 66105 RM1-IL18 cells were implant-
ed orthotopically in syngeneic, immunologically intact C57BL/6 mice. A)
Post mortem tumor weights, 14 days after cell injection are shown. Mice
were treated with IL-18-neutralizing antibody (aIL-18), and/or IFN-c
neutralizing antibody (aIFN-c) and/or A2 isotype control antibody (Ctrl),
as indicated. Statistical analysis was performed by one-way ANOVA
followed by Tukey’s multiple comparison test. B) & C) Semi-quantitative
assessment of CD8+ and CD4+ T cells, in tumors from mice in (A).
Histological sections were immunohistochemically stained for CD8 (B)
and CD4 (C) and the number of each T cell type per microscopic field at
2006magnification was determined as either zero, 1–10, 11–50, or .50
as described in Methods and Materials. Statistical analysis was
performed by two-way ANOVA followed by Bonferroni post test.
* p value 0.01 to 0.05, ** p value 0.001 to 0.01, *** p,0.001.
doi:10.1371/journal.pone.0024241.g002
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had no effect on tumor growth as all tumors progressed (Fig. 6 B). IL-
18 treatment resulted in complete tumor regression in 3 of 10 mice
(Fig. 6 A). Once the IL-18 treatment was started, the tumors either
regressed or remained relatively stable through to day 20 (Fig. 6 B).
In contrast intraperitoneal injection of IL-18 had no effect on tumor
growth (Fig. 6 A). Immunohistochemistry of tumors injected with IL-
18 showed greater infiltration of macrophages compared to control
groups (Fig. 6 C &D). No difference in the numbers of CD4+T cells,
CD8+ T cells or NK cells were seen between the two groups (data
not shown). IFN-c and GM-CSF and IL-4 were not present at
detectable levels in the serum of these mice and there was no
difference in IL-12 or RANTES between treatments. However, aIL-
18 treatment correlated with higher levels of MCP-1 (Fig. 6 E).
Discussion
This study demonstrates that IL-18 in the RM1 tumor
environment, achieved either by IL-18 gene-introduction or direct
Figure 3. Immune cell infiltration of orthotopic RM1-IL18 tumors. Histochemical and immunohistochemical staining of intraprostatic RM1-
IL18 tumors from C57BL/6 mice described in the legend to Fig. 2 A, without (A, C, E, G & I) or with (B, D, F, H & J) aIL-18 treatment.
Immunohistochemical staining was performed with anti-CD8 (A & B), anti-CD4 (C & D), anti-F4/80 for macrophages (E & F) and anti-asialo-GM1 for NK
cells (I & J). H&E staining of tumor sections shows neutrophil infiltration (G & H), indicated by green arrowheads.
doi:10.1371/journal.pone.0024241.g003
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injection can slow the growth of both subcutaneous and orthotopic
tumors in in vivo models, thus provides proof of concept that IL-18
has potential as an immunotherapeutic agent for prostate cancer.
IL-18 either prevented the establishment or at least slowed the
growth of subcutaneous tumors, but perhaps more importantly,
slowed the growth of orthotopic tumors. The difference in growth
patterns at the two anatomical sites highlights the importance of
using orthotopic models to assess not only the effect of immuno-
therapy on tumour growth but also the mechanisms involved in
mediating such effects. The anti-tumor effect was dependent on
IFN-c as inactivation of this cytokine rendered IL-18 incapable
of inducing tumor stasis. Adaptive immune mechanisms were
demonstrated to be important in mediating the anti-tumor effects of
IL-18, and innate mechanisms are also implicated.
Generation of intraprostatic RM1 tumors in syngeneic mice is a
useful model of prostate cancer in humans and allows assessment of
the anti-tumor immune response in this organ rather than assuming
that the results will be similar to those found with heterotropic
implantation sites such as sc. We know that tumor take rates and
growth kinetics will vary depending on the anatomical site of
implantation due to factors which are likely to include the nature of
the stroma in which the cells are transplanted, the local vasculature,
the prevalence of locally-produced tumor growth factors, the
anti-tumor immune response at the site of implantation, and in
studies where therapeutic interventions are assessed, the local
bio-availability of the compound being tested. Thus orthotopic
models are preferable for modeling human disease. Although RM1
tumors grew subcutaneously, orthotopic implantation of these tumor
cells proved more conducive for tumor growth (Fig. 1 A-D). Our
results also suggested that there are significant differences in the
nature of the immune response to tumors at the different anatomical
sites, a finding which is not unexpected, and we are exploring these
differences further. Because of this, we employed intraprostatic
implantation of RM1 cells in further experiments to investigate the
anti-tumor mechanisms induced by IL-18 in the prostate. Further-
more, whilst several reports compare the in vivo growth characteristics
of derivative cell lines transfected with different constructs to
demonstrate the tumor suppressive effects of IL-18 [20,22,23,25],
in our studies the use of an IL-18 neutralizing antibody confirms that
any observed difference in tumor growth can be attributed to the
cytokine and is not due to inherent differences between cell lines.
In all our experiments, regardless of the site of injection of the
tumor cells or method of delivery, IL-18 reduced the tumor
burden significantly. Of interest also is the observation that
neutralization of endogenous IL-18 allows tumors to grow more
rapidly indicating that in this model IL-18 is important for tumor
immune surveillance (Fig. 1 C). In line with this observation, single
nucleotide polymorphisms (SNPs) within the human IL-18 gene
that are associated with lower promoter activity and lower gene
expression [41], may influence susceptibility to certain cancers
Figure 4. Both innate and adaptive immune mechanisms are involved in inhibition of tumor growth by IL-18. 66105 RM1-IL18 cells
were implanted orthotopically in syngeneic, immunologically intact (wild-type) C57BL/6 mice or immunodeficient C57BL/6 RAG-12/2 mice (one
single experiment). A) Post mortem tumor weights 14 days after cell injection is shown. Mice were treated with (aIL-18) or without (Ctrl) the IL-18-
neutralizing antibody. Statistical analysis was performed by one-way ANOVA followed by Newman-Keuls multiple comparison test. Significant
p values are shown. * p value 0.01 to 0.05, ** p value 0.001 to 0.01, *** p,0.001 B) Tumor-draining lymph nodes of normal C57BL/6 mice with
orthotopic RM1-IL18 tumors show increased cellularity but a decrease in lymphocytes as a percentage of total cells (C & D) when IL-18 is neutralized
as assessed by flow-cytometry. Results shown are for pooled para-aortic lymph nodes from normal C57BL/6 mice described in Figure 4 A.
doi:10.1371/journal.pone.0024241.g004
IL-18 Inhibits Murine Prostate Cancer Growth
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24241
including prostate cancer [42], nasopharyngeal cancer [43] and
esophageal squamous cell carcinoma [44]. Moreover, human
prostate cancer cell lines and clinical PCa specimens are reported
to express IL-18 receptor a [45] and IL-18 expression was
associated with better patient outcome. However, systemic
administration of recombinant human IL-18 into cancer patients,
as reported in three clinical trials, did not lead to overt anti-tumor
efficacy [46,47,48]. Based on our work, we speculate that this
route of administration of IL-18 does not deliver therapeutic doses
of the cytokine to the tumor to induce anti-tumor responses.
Similar to these results, systemic administration of IL-18 could not
hinder the growth of subcutaneous tumors (Fig. 6 A). IL-18 only
inhibited tumor growth when administered directly into the tumor
mass (intralesional) (Fig. 6 A) or if the cytokine was secreted by
tumor cells. This indicates that IL-18 is far more effective at the
tumor site in generating anti-tumor effects. Intratumoral injection
of immune-modulatory compounds is a potentially feasible
delivery approach, with administration of recombinant IL-12
(for head and neck squamous cell carcinoma (H&NSCC) [49] and
viral vectors encoding cytokine genes IFN-c [50], GM-CSF [51]
(both for melanoma) and IL-12 [52] (colorectal and pancreatic
cancers) already being evaluated in clinical trials. In previous
studies, numerous mechanisms have been shown to be involved in
mediating the anti-tumor effects of IL-18. These include the
recruitment and activation of various innate and adaptive immune
cells and inhibition of angiogenesis. We explored the involvement
of a number of these mechanisms in our studies.
IL-18 is a potent inducer of IFN-c production by T cells, NK
cells and macrophages and is synergistic in this function with IL-12
[16]. The results presented here clearly demonstrate that for
intraprostatic tumors the anti-tumor effects of IL-18 are primarily
mediated through IFN-c because neutralization of IFN-c
completely abolished IL-18-mediated protection (Fig. 2 A). This
finding is consistent with that of Nagai et al. where IFN-c was
required for the tumor inhibitory effects of IL-18 on B16
melanomas using a gene-transfer approach, although the main
mechanism reported in this case was via inhibition of tumor
angiogenesis [20]. Osaki et al., however, showed that the tumor
suppressive effects of IL-18 on CL-8 tumors are not completely
impaired in IFN-c gene KO mice [30].
Tumors grew more rapidly in RAG12/2 mice, which lack T
and B cells, than in normal immunologically intact mice (Fig. 4 A)
and together with the depletion results presented in Fig. 5 A & B,
indicate that adaptive immunity is involved in the control of
tumor growth. Furthermore, in immunologically intact mice, the
presence of IL-18 induced significantly greater infiltrations of
CD8+ T cells and CD4+ T cells (Fig. 2 B & C, Fig. 3 A–D) further
supporting a role for these cells. In addition, although the tumor
draining lymph nodes of IL-18-treated mice had fewer CD4+ T
cells, CD8+ T cells and NK cells per lymph node, they represented
a higher percentage of lymph node cellularity than those of the
aIL-18 group (Fig. 4 B–D). Although CD4+ and CD8+ cells
represent a smaller percentage of the total cells in the lymph nodes
in mice treated with anti-IL18, the absolute numbers of these cells
Figure 5. Anti-tumor effects of IL-18 are mediated by CD4+ and CD8+ T cells, and NK cells. C57BL/6 mice were implanted with 26106
RM1(BM)/IL-18lo-luc cells orthotopically, and treated with 500 mg of either the aIL-18 antibody or the A2 isotype control (Ctrl) antibody. Some mice
were treated with aCD4 (GK1.5), aCD8 (2.43) or aNK (Asialo GM1), as indicated (See Materials and Methods). All mice depleted of any cell subset also
received the A2 isotype control antibody. A) post-mortem tumor weights on day 17. Statistical analysis was performed by one-way ANOVA followed
by Dunnett’s multiple comparison’s test to the corresponding Ctrl. * p value 0.01 to 0.05, ** p value 0.001 to 0.01, *** p,0.001. B) Average tumor
bioluminescence in each treatment group at three time points. Representative images of tumor bioluminescence in mice treated with Ctrl (C) or aIL-
18 antibodies (D).
doi:10.1371/journal.pone.0024241.g005
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in the draining lymph nodes is higher in the anti-IL18 treated
mice. This is not surprising given that these measurements were
done following necropsy of mice at the end of the experiment. At
this late stage of the experiment the tumors in the treated mice are
significantly larger than in the untreated mice and concentration
of the neutralizing antibody available will be significantly reduced
due to normal metabolic processes (half life of IgG1 is ,21 days)
and consumption. Thus at the end of the experiment, even though
there appears to be a significant immune response to the tumour,
it is ineffective against a large established tumor. Similar findings
have been described previously in concomitant immunity studies
[53,54]. The importance of these cells in the anti-tumor effect are
not surprising given that IL-18 is chemoattractive for T cells [55],
drives the differentiation of CD4+ T cells to the Th1 phenotype,
induces the proliferation and enhances the cytotoxicity of T
cells and NK cells [16] and induces the maturation of dendritic
cells [56].
Our results also suggest a role for innate immunity in IL-18-
induced tumor suppression. In RAG12/2 mice, which fail to
develop adaptive immunity, the presence of IL-18 resulted in
significantly smaller tumors (Fig. 4 A). Furthermore, in both
RAG12/2 and immunologically intact mice, IL-18 correlated with
greater tumor infiltration of macrophages (Fig. 3 E & F, Figure S3 A
& B) and neutrophils (Fig. 3 G & H, Figure S3 C & D). An
involvement of macrophages in the anti-tumour effect of IL-18 is
further supported by the finding that intratumoral injection of
rIL-18 into subcutaneous tumours elevated serum levels of MCP-
1 (Fig. 6 E). Macrophages express the IL-18R, and can be
activated by and secrete IFN-c [17], and may be central to the
development of adaptive immunity induced by IL-18. Kito et al.
demonstrated that macrophages activated through stimulation
with IL-12 and IL-18, produce IFN-c which induces nitric oxide
secretion that is cytotoxic for tumors [17]. IL-18 is chemoat-
tractive for neutrophils [18], induces the expression of IL-8 which
Figure 6. Intratumoral injection of rIL-18 inhibits growth of subcutaneous tumors. C57BL/6 mice were injected subcutaneously with
26106 RM1(BM)/B4H7-luc cells. IL-18 (1.5 ug) or vehicle (Ctrl) was injected intratumorally in 15 ml volume, or 100 ml when injected i.p., for 5
consecutive once tumors reached 6 mm66 mm in size. A) post-mortem tumor weights from two independent experiments which showed similar
results. Statistical analysis was performed by non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparison’s test. B) Growth rates of
subcutaneous tumors injected intratumorally with IL-18 or vehicle (Ctrl) are shown from one representative experiment. Staining for F4/80
(macrophages) in tumors treated with IL-18 (C) or vehicle (D) is shown. E) Concentration of cytokines in mice serum from Fig. 6 A is shown. Graphs
show median concentration and range. Statistical analysis was performed by non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0024241.g006
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is chemotactic for neutrophils [57] and under proinflammatory
conditions promotes neutrophils to secrete cytotoxic molecules
[58]. Interestingly, macrophages appeared to localize in the
viable regions (Ki-67+) of the tumors, whilst neutrophils were
almost exclusively found in apoptotic areas (caspase-3+) (Figure
S2 A–E). NK cells may play a role as depletion of this cell type
appeared to inhibit the anti-tumor effect of IL-18, although the
difference was not statistically significant in these studies (Fig. 5
A). There was no difference in the number of NK cell infiltration
in tumors, in the presence or absence of IL-18 (Fig. 3 I & J,
Figure S3 E & F), but may be functionally enhanced by IL-18 as
they express the IL-18 receptor [13].
The reported mechanisms of action of IL-18-induced anti-
tumor immunity in previous studies have varied. Osaki et al.
showed that intraperitoneal injection of recombinant IL-18 for 7
consecutive days either prior to, or after intradermal implantation
of CL-8 melanoma cells suppressed tumor growth [30]. This anti-
tumor effect was dependent on NK cells, although the importance
of T cells was not defined [30]. In contrast to our data, IL-18
treatment did not change tumor infiltration of CD4+ T cells or
macrophages, and reduced the number of CD8+ T cells. Several
differences in the experimental models can account for the
differences in results. Our RM1 tumors constitutively express IL-
18 locally in the tumor resulting in the observed influx of CD4+ T
cells, CD8+ T cells and macrophages into the tumors, while the
Osaki et al. model used intraperitoneal injection of IL-18 which is
less likely to induce local tumor effects but more likely to induce
systemic effects, in this case NK cell activation. Secondly, Osaki
et al. reported a reduction in tumor-infiltrating CD8+ T cells in
tumors that were excised at day 6 of tumor growth [30], a point at
which the adaptive immune response is still developing and innate
responses are likely to dominate. In contrast, our studies extended
14 days after tumor implantation and thus the adaptive immune
response is likely to dominate. Differences in the local tumor
microenvironment (intradermal vs intraprostatic and subcutane-
ous) and the inherent immunogenecity of the tumor cells will also
influence the effects of the cytokine.
Yoshimura et al. [22] showed that IL-18-gene transfected
CT26 tumors grew more rapidly when CD4+ T cells and CD8+ T
cells were depleted, and tumors from non-depleted mice
contained large numbers of infiltrating CD8+ T cells, results
comparable to our data. In that study, depletion of NK cells did
not affect the tumor growth [22]. However, Micallef et al. showed
that NK cells are required for IL-18-mediated control of
intraperitoneal Meth A sarcoma cells when IL-18 is delivered
ip 3 days and 6 hours prior to tumor cell injection [27]. Nagai et
al., showed that neither CD8+ T cells nor NK cells were involved
in the inhibition of IL-18-gene-transfected B16 melanomas as
depletion of these cell types had no effect on tumor growth,
but growth inhibition was mediated through IL-18-mediated
angiostasis [20].
Although both approaches in delivering IL-18 inhibited tumor
growth, the mechanisms of action are seemingly different.
Intratumoral injection of IL-18 resulted in significant infiltration
of macrophages but not T cells within the tumor mass. The lack of
correlation between IL-18 and T cell numbers in these tumors
contrasts with the situation of IL-18-secreting tumors. This
difference is likely to be attributed to the varied route of
administration of IL-18: daily injections into pre-established
tumors for 5 consecutive days starting from day 6, versus IL-18
expression by tumors throughout. Hence, the kinetics, duration
and the magnitude of immune stimulation are different. Other
studies have also shown that intratumoral injection of IL-18 can
inhibit tumor growth. Kikuchi et al. showed that intratumoral but
not intraperitoneal injection of rIL-18 into murine SR-B10A
gliomas in the frontal lobe of mice significantly prolonged
their survival. This effect was mediated by NK cells but not
CD4+ or CD8+ T cells [59]. Cao et al. also showed that
intratumoral injection of IL-18 significantly inhibited the
growth of murine T241 fibrosarcomas, although the reported
mechanism of action in this case was inhibition of tumor
angiogenesis [31].
We have demonstrated in an immunocompetent orthotopic
model of prostate cancer that intratumoral IL-18 has the ability to
inhibit tumor growth. The anti-tumor effect is mediated by
induction of IFN-c expression by IL-18, resulting in stimulation of
both the innate and adaptive immune. These results confirm that
IL-18 holds promise as an immunotherapeutic agent for the
treatment of prostate cancer.
Supporting Information
Figure S1 Characterisation of cell lines. A) Activated
splenic T cells were incubated with various concentrations of RM1-
IL18 conditioned media and IFN-c production was detected by
ELISA. Increasing concentrations of CM induced IFN-c production
in a dose-dependent manner. B) RM1-IL18 tumors stained for IL-18
by immunohistochemistry (left panel); negative isotype control (right
panel). C) As few as 400 RM1(BM)/IL-18lo-luc cells can be detected
in vitro by bioluminescent imaging after addition of luciferin.
(TIF)
Figure S2 Immunohistochemical staining for markers
of apoptosis and cell proliferation in orthtopic RM1-
IL18 tumours. Representative images of tumours stained for
caspase-3 (A & B) for apoptotic cells and Ki-67 (C & D) for
proliferating cells is shown. E) The percentage of tumor sections
(6 standard error of mean) stained with the pro-apoptotic
molecule caspase-3 (upper panel) and the proliferation-dependent
protein Ki-67 (lower panel) was estimated after immunohisto-
chemical staining of sections from multiple tumors. All treatments
were compared to the Ctrl group using one-way ANOVA followed
by Tukey’s multiple comparison post test. Statistically significant p
values are indicated for comparisons between treatment groups
the corresponding Ctrl, * p value 0.01 to 0.05, ** p value 0.001 to
0.01, *** p,0.001.
(TIF)
Figure S3 IL-18 increases tumor-infiltration of macro-
phages and neutrophils but not NK cells in C57BL/6
RAG1-/- mice. Histochemical and immunohistochemical stain-
ing of intraprostatic RM1-IL18 tumors from the RAG1-/- mice
described in the legend to Fig. 4 A, without (A, C & E) or with (B,
D & F) the IL-18-neutralizing antibody. Immunohistochemical
staining was performed with anti-F4/80 for macrophages (A & B)
and anti-asialo-GM1 for NK cells (E & F). Histochemical staining
(C & D) showing neutrophil infiltration indicated by green
arrowheads is shown.
(TIF)
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